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Hepatocyte growth factor (HGF) is involved in at least three important steps of 
epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) resistance 
in EGFR mutant lung cancer, inducing resistance to reversible EGFR-TKIs by 
restoring Met/Gab1/PI3K/Akt pathways, inducing resistance to next-generation 
EGFR-TKIs (irreversible TKI and mutant-selective EGFR-TKI), and accelerating 
the emergence of EGFR-TKI-resistant clones by continuous exposure to HGF. 
Therefore, HGF may be an ideal target for overcoming EGFR-TKI resistance in 
EGFR mutant lung cancer. 
 In pre-clinical experiments, we have tested whether a new Met kinase 
inhibitor, E7050, which is currently under evaluation in clinical trials, could 
overcome these three HGF-induced EGFR-TKI resistance mechanisms. Our 
findings suggest that E7050 may be useful for overcoming HGF-induced 
resistance to gefitinib and next-generation EGFR-TKIs in EGFR mutant lung 
cancer.  
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Abstract 
Purpose: Hepatocyte growth factor (HGF) induces resistance to reversible and 
irreversible epidermal growth factor receptor tyrosine kinase inhibitors 
(EGFR-TKIs) in EGFR mutant lung cancer cells by activating Met and the 
downstream PI3K/Akt pathway. Moreover, continuous exposure to HGF 
accelerates the emergence of EGFR-TKI-resistant clones. We assayed whether 
a new Met kinase inhibitor, E7050, which is currently being evaluated in clinical 
trials, could overcome these three mechanisms of resistance to EGFR-TKIs.  
Experimental design: The effects of E7050 on HGF-induced resistance to 
reversible (gefitinib), irreversible (BIBW2992), and mutant-selective (WZ4002) 
EGFR-TKIs were determined using the EGFR-mutant human lung cancer cell 
lines PC-9 and HCC827 with an exon 19 deletion, and H1975 with an T790M 
secondary mutation. PC-9 cells were mixed with HGF-producing fibroblasts, 
MRC-5 cells, and subcutaneously inoculated into SCID mice and the therapeutic 
effects of E7050 plus gefitinib were assayed. 
Results: E7050 circumvented resistance to all of the reversible, irreversible, and 
mutant-selective EGFR-TKIs induced by exogenous and/or endogenous HGF in 
EGFR mutant lung cancer cell lines, by blocking the Met/Gab1/PI3K/Akt pathway 
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in vitro. E7050 also prevented the emergence of gefitinib-resistant HCC827 cells 
induced by continuous exposure to HGF. In the in vivo model, E7050 plus 
gefitinib resulted in marked regression of tumor growth associated with inhibition 
of Akt phosphorylation in cancer cells. 
Conclusions: A new Met kinase inhibitor, E7050, reverses the three 
HGF-induced mechanisms of gefitinib resistance, suggesting that E7050 may 
overcome HGF-induced resistance to gefitinib and next-generation EGFR-TKIs.  
 American Association for Cancer Research Copyright © 2012 
 on February 14, 2012clincancerres.aacrjournals.orgDownloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on February 8, 2012; DOI:10.1158/1078-0432.CCR-11-1171
 5
Introduction 
The reversible epidermal growth factor receptor (EGFR)-tyrosine kinase 
inhibitors (TKIs) gefitinib and erlotinib show dramatic therapeutic efficacy in 
patients with EGFR-activating mutations, such as in-frame deletions of exon 19 
and the L858 point mutation in exon 21 (1, 2). Recent clinical trials have 
demonstrated that these TKIs induced much higher response rates and longer 
progression-free survival than standard first-line cytotoxic chemotherapy in 
patients with EGFR mutant lung cancer (3, 4). Almost all patients, however, 
develop acquired resistance to EGFR-TKIs after varying periods of time (5). In 
addition, 20% – 30% of patients with EGFR-activating mutations show intrinsic 
resistance to EGFR-TKIs (5). Therefore, intrinsic and acquired resistances to 
EGFR-TKIs are major problems in the management of EGFR mutant lung 
cancer. 
Three clinically relevant mechanisms have been reported to induce acquired 
resistance to EGFR-TKIs in EGFR mutant lung cancer—EGFR T790M 
secondary mutation (6, 7), Met gene amplification (8), and hepatocyte growth 
factor (HGF) overexpression (9). We found that HGF overexpression is involved 
not only in acquired but in intrinsic resistance to EGFR-TKIs (9). HGF has been 
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shown to play at least three important roles in EGFR-TKI resistance in EGFR 
mutant lung cancer. First, HGF induces resistance to the reversible EGFR-TKIs 
gefitinib and erlotinib by restoring MetGab1/PI3K/Akt pathways (9, 10). Second, 
continuous exposure to HGF accelerates the expansion of preexisting 
Met-amplified cancer cells and facilitates Met amplification-mediated resistance 
during EGFR-TKI treatment (10). Third, after lung cancer cells acquire 
resistance to reversible EGFR-TKIs, HGF induces the resistance of cells with 
T790M secondary mutation to irreversible EGFR-TKIs (11). These findings 
indicate that HGF is an ideal target for overcoming EGFR-TKI resistance in 
EGFR mutant lung cancer.  
There are several possible strategies for inhibiting HGF-Met signaling, 
including anti-HGF neutralizing antibody, HGF antagonist (NK4), Met tyrosine 
kinase inhibitors, and inhibitors of downstream molecules, such as PI3K, Akt, 
and mTOR (12). Previously, we showed that anti-HGF antibody (13), NK4 (13), 
and PI3K inhibitors (14) were effective in overcoming HGF-induced gefitinib 
resistance. Many Met-TKIs have therefore been developed and are expected to 
reverse HGF-induced resistance to EGFR-TKIs (10, 15).  
E7050 is an orally active Met-TKI (16) that has been shown to inhibit the 
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phosphorylation of Met, including amplified Met, and to suppress the growth of 
several types of cancer cells with Met amplification. Based on favorable 
pre-clinical data, a phase I clinical trial of E7050 is currently in progress. We 
have assessed whether E7050 can overcome the three HGF-induced resistance 
mechanisms to EGFR-TKIs. 
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Materials and Methods 
Cell culture  
The EGFR mutant human lung adenocarcinoma cell lines PC-9 and HCC827 
were purchased from Immuno-Biological Laboratories Co. (Takasaki, Gunma, 
Japan) and the American Type Culture Collection (Manassas, VA), respectively. 
The human embryonic lung fibroblast cell line MRC-5 was purchased from 
Health Science Research Resources Bank (Sen-nan, Japan). MRC-5 (P 30-35) 
cells were maintained in DMEM with 10% fetal bovine serum (FBS). PC-9 and 
HCC827 cells were maintained in RPMI 1640 medium with 10% FBS. 
Reagents  
E7050 was synthesized by Eizai Co., Ltd., Ibaraki, Japan (16). Gefitinib was 
obtained from AstraZeneca (Cheshire, UK). The irreversible EGFR-TKI, 
BIBW2992, and the mutant-selective EGFR-TKI, WZ4002, were purchased from 
Selleck (Houston, TX). Recombinant HGF and anti-human HGF antibody were 
prepared as described (17).  
Cell growth assay  
Cell growth was measured using the MTT [3-(4,5-dimethylthiazol-2-yl)-2, 
5-diphenyl tetrazolium] dye reduction method (18). Tumor cells were plated at a 
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density of 2×103 cells/100 μl/well into 96-well plates in RPMI1640 medium with 
10% FBS. After 24-h incubation, various reagents were added to each well, and 
the cells incubated for a further 72 h, followed by the addition of 50 μl of MTT 
solution (2 mg/ml; Sigma, St. Louis, MO) to each well and further incubation for 2 
h. The media containing MTT solution were removed, and the dark blue crystals 
were dissolved by adding 100 μl of DMSO. The absorbance of each well was 
measured with a microplate reader at test and reference wavelengths of 550 and 
630 nm, respectively. The percentage of growth is shown relative to untreated 
controls. Each reagent and concentration was tested at least in triplicate during 
each experiment, and each experiment was performed at least 3 times.  
Antibodies and western blotting 
Cells were lysed in cell lysis buffer containing phosphatase and proteinase 
inhibitor cocktails (Sigma), and protein concentrations were determined using a 
BCA Protein Assay Kit (Pierce Biotechnology, Rockford, IL). For the detection of 
phosphorylated Met in subcutaneous tumors, 10mg tumor lysates were 
immunoprecipitaed with anti-Met (25H2) antibody. Total protein (40 μg/lane) was 
resolved by SDS-polyacrylamide gel electrophoresis, and the proteins were 
transferred onto PVDF membranes (Bio-Rad, Hercules, CA). After washing 4 
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times, the membranes were incubated with Blocking One (Nacalai Tesque Inc., 
Kyoto, Japan) for 1 h at room temperature, followed by overnight incubation at 
4°C with primary antibodies to Met (25H2), phospho-Met (Y1234/Y1235) (3D7), 
phospho EGFR (Y1068), ErbB3 (1B2), phospho-ErbB3 (Tyr1289) (21D3), Gab1 
(#3232), phospho-Gab1 (Y627)(C32H2), Akt, and phospho-Akt (Ser473) 
(736E11) (1:1000 each; Cell Signaling Technology, Beverly, MA); and 
anti-human EGFR (1 μg/ml) antibody (R&D Systems, Minneapolis, MN). After 
washing 3 times, the membranes were incubated for 1 h at room temperature 
with species-specific horseradish peroxidase-conjugated secondary antibodies. 
Immunoreactive bands were visualized using SuperSignal West Dura Extended 
Duration Substrate Enhanced Chemiluminescent Substrate (Pierce 
Biotechnology). Each experiment was performed at least 3 times independently. 
HGF production  
Cells (2×105) were cultured in RPMI1640 medium with 10% FBS for 24 h, 
washed with PBS and incubated for 48 h in 2 ml of the same medium. The 
culture medium was harvested and centrifuged, and the supernatant was stored 
at –70°C until analysis. HGF concentrations were measured by IMMUNIS HGF 
EIA (Institute of Immunology, Tokyo, Japan), with a detection limit of 100 pg/ml, 
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according to the manufacturer’s instructions. All culture supernatants were tested 
in duplicate. Color intensity was measured at 450 nm using a spectrophotometric 
plate reader. Growth factor concentrations were determined by comparison with 
standard curves.  
HGF gene transfection  
One day before transfection, aliquots of 1×105 HCC827 cells in 1 ml of 
antibiotic-free medium were plated on 6-well plates. Full-length HGF cDNA 
cloned into the BCMGSneo expression vector (19) was transfected using 
Lipofectamine 2000 in accordance with the manufacturer’s instructions. After 
24-h incubation, the cells were washed with PBS and incubated for an additional 
72 h in antibiotic-containing medium, followed by selection in G418 sulfate 
(Calbiochem, La Jolla, CA). After limiting dilution, HGF-producing cells, 
HCC827/HGF, were established. HGF production by HCC827/HGF cells was 
confirmed by ELISA. 
RNA interference assay 
Duplexed Stealth™ RNAi (Invitrogen, Carlsbad, CA) against MET, ErbB3, 
and Gab1, and Stealth™ RNAi Negative Control Low GC Duplex #3 (Invitrogen) 
were used for RNA interference assays. One day before transfection, aliquots of 
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2×104 tumor cells in 400 μl of antibiotic-free medium were plated on 24-well 
plates. After incubation for 24 h, the cells were transfected with siRNA (50 pmol) 
or scrambled RNA using Lipofectamine 2000 (1 μl) in accordance with the 
manufacturer’s instructions. After 24-h incubation, the cells were washed with 
PBS and incubated with or without various reagents for an additional 72 h in 
antibiotic-containing medium. Cell growth was measured using a Cell Counting 
Kit-8 (Dojin, Tokyo, Japan) in accordance with the manufacturer’s instructions. 
Knockdown of MET, ErbB3, Gab1, and, Shc1 was confirmed by western blotting. 
Each reagent and concentration was tested at least in triplicate during each 
experiment, and each experiment was performed at least 3 times. 
Detection of Met amplification 
Cell block sections (4 μm thick) were subjected to dual-color fluorescence in situ 
hybridization (FISH) using a MET/CEP7 probe cocktail (Kreatech Diagnostics, 
Amsterdam, The Netherlands) according to the manufacturer’s instructions. 
Staining was evaluated as described (20). 
Xenograft studies in SCID mice 
Suspensions of PC-9 cells (5×106) mixed with MRC-5 cells (5×106) were injected 
subcutaneously into the backs of 5-week-old female SCID mice (Clea, Tokyo, 
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Japan), as described (13). After 4 days (tumor diameter > 5 mm), mice were 
randomly allocated into groups of 6 animals each to receive E7050 (50 
mg/kg/day) and/or gefitinib (25 mg/kg/day) by oral gavage. Tumor volume was 
calculated as mm3=width2×length/2. All animal experiments were performed in 
compliance with the Guidelines for the Institute for Experimental Animals, 
Kanazawa University Advanced Science Research Center (Approval number: 
AP-081088).  
Immunohistochemistry  
Frozen sections (5 µm thick) of xenograft tumors were fixed with cold 
acetone and washed with PBS. After blocking endogenous peroxidase activity 
with 3% aqueous H2O2 solution for 10 min, the sections were incubated with 5% 
normal horse serum, followed by overnight incubation at 4°C with 
anti-phospho-Akt antibody (Ser473) (736E11, 1:100 dilution). The sections were 
washed with PBS, incubated with biotin-conjugated anti-rabbit IgG (1:200 
dilution) for 30 min at room temperature, and incubated for 30 min with 
avidin–biotin–peroxidase complex (ABC) using a Vectastain ABC kit (Vector 
Laboratories, Burlingame, CA). Staining was detected using the DAB 
(3,3’-diaminobenzidine tetrahydrochloride) Liquid System (DakoCytomation, 
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Glostrup, Denmark). Samples from which primary antibodies had been omitted 
served as negative controls. 
 
Statistical analysis  
Between group differences were analyzed by one-way ANOVA, with 
P-values <0.05 for overall comparisons tested by post hoc pairwise comparisons 
using the Newman-Keuls multiple comparison test. All statistical analyses were 
performed using GraphPad Prism Ver. 4.01 (GraphPad Software, Inc., San 
Diego, CA). 
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Results 
E7050 reverses resistance to EGFR-TKIs induced by exogenous HGF 
PC-9 and HCC827 cells were highly sensitive to gefitinib (Fig. 1A), while 
exogenously added HGF induced resistance to gefitinib in both cell lines (9, 13, 
14). Although E7050 did not affect the growth of PC-9 or HCC827 cells at 
concentrations <3 μM, the combination of E7050 with gefitinib reversed 
HGF-induced resistance of both cell lines in a concentration-dependent manner 
(Fig. 1B).  
 We previously reported that stromal fibroblasts are a source of exogenous HGF 
for EGFR-TKI naïve NSCLC and that fibroblast-derived HGF induces resistance 
to gefitinib and erlotinib in PC-9 and HCC827 cells (13). Although E7050 had no 
effect on the growth or production of HGF or VEGF by MRC-5 cells (HGF-high 
producing fibroblasts) or PC-9 cells (data not shown), it reversed the gefitinib 
resistance of PC-9 cells induced by co-culturing with MRC-5 cells (Fig. 1C), 
indicating that E7050 can reverse the EGFR-TKI resistance induced by 
exogenous HGF in vitro. 
E7050 reverses resistance to EGFR-TKIs induced by endogenous HGF 
We have shown that HGF is present in tumor cells of NSCLC patients with 
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acquired resistance to EGFR-TKIs, and that transient HGF gene transfection 
into PC-9 cells resulted in resistance to EGFR-TKIs (9). We therefore generated 
a stable HGF gene transfectant in HCC827 cells (HCC827/HGF) and assessed 
the effects of continuously produced endogenous HGF. HCC827/HGF, but not 
HCC827 or the vector control HCC827/Vec, cells secreted high levels of HGF 
and became resistant to gefitinib (Fig. 2A, B). Anti-HGF antibody reversed the 
gefitinib resistance of HCC827/HGF cells (Supplementary Fig. S1), indicating 
that endogenously produced HGF induced gefitinib resistance in this cell line. 
Although the combination of E7050 plus gefitinib successfully reversed the 
resistance of HCC827/HGF cells, E7050 alone did not inhibit the proliferation of 
HCC827/HGF cells (Fig. 2B).  
Using western blotting, we examined the effects of E7050 on signal 
transduction in HCC827/Vec and HCC827/HGF cells. We found that gefitinib 
inhibited the phosphorylation of EGFR and ErbB3 in HCC827/Vec cells, thereby 
inhibiting the phosphorylation of Akt and ERK1/2. However, gefitinib failed to 
inhibit phosphorylation of Akt in the presence of HGF. E7050 suppressed the 
constitutive phosphorylation of Met, but not of EGFR, ErbB3, and downstream 
Akt and ERK1/2. While HGF stimulated the phosphorylation of Met, E7050 plus 
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gefitinib inhibited this HGF-induced Met phosphorylation, and strongly 
suppressed the phosphorylation of Gab1, Akt, and ERK1/2 (Fig. 2C).  
The amount of Met protein was decreased in HCC827/HGF cells, compared 
with HCC827/Vec cells. This could be a result of Met downregulation by 
persistent HGF stimulation, as also observed in a previous report (21). In 
contrast, the degree of Met phosphorylation was higher in HCC827/HGF than in 
HCC827/Vec cells. Gefitinib inhibited the phosphorylation of EGFR and ErbB3, 
but not of Akt in HCC827/HGF cells. The combination of E7050 and gefitinib 
inhibited the phosphorylation of both Met and Akt (Fig. 2C). These results 
suggest that E7050 reversed HGF-induced gefitinib resistance by inhibiting the 
Met/Gab1/PI3K/Akt pathway. 
To confirm that the E7050 reversal of gefitinib resistance in HCC827/HGF 
cells was due to the inhibition of Met/Gab1, we transfected cells with siRNA 
specific for Met or Gab1. Transfection of ErbB3, Met, or Gab1 siRNA 
successfully knocked down the expression of the corresponding protein (Fig. 
2D). While scrambled or ErbB3 siRNA did not reverse the gefitinib resistance of 
HCC827/HGF cells, siRNAs for Met and Gab1 sensitized these cells to gefitinib 
(Fig. 2D), indicating that E7050 reverses gefitinib resistance in HCC827/HGF 
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cells by inhibiting the Met/Gab1 pathway. 
E7050 reverses HGF-induced resistance to next-generation EGFR-TKIs in 
H1975 cells 
Next-generation EGFR-TKIs, irreversible TKIs (22 – 24) and mutant EGFR 
selective TKIs (25) have been developed to treat gefitinib-resistant tumors 
caused by the EGFR T790M secondary mutation. H1975 cells with the EGFR 
mutations L858R and T790M mutations were resistant to reversible EGFR-TKIs, 
gefitinib and erlotinib (data not shown), but were sensitive to BIBW2992, an 
irreversible EGFR-TKI, and WZ4002, a mutant-selective EGFR-TKI (Fig. 3). 
HGF markedly induced resistance to BIBW2992 and WZ4002, whereas E7050 
efficiently reversed the HGF-induced resistance to both BIBW2992 and WZ4002. 
These results indicate that E7050 can overcome HGF-induced resistance not 
only to gefitinib but to next-generation EGFR-TKIs, including irreversible and 
mutant-selective EGFR-TKIs.  
E7050 prevents emergence of gefitinib-resistant HCC827 cells induced by 
continuous exposure to HGF 
As HGF has been reported to accelerate the expansion of preexisting 
Met-amplified HCC827 cells and to facilitate Met amplification-mediated 
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resistance during EGFR-TKI treatment (10), we examined the effects of E7050 
on these phenomena. Although HCC827 cells did not produce viable colonies 
after 30 days of continuous exposure to gefitinib alone (Fig. 4A, B), these cells 
produced many colonies after exposure to both HGF and gefitinib. In contrast to 
previous findings (10), the percentage of cells with Met amplification was not 
increased when compared with parental HCC827 cells. The reason for this 
discrepancy remains unclear. Western blot analyses revealed that while the 
resultant cells expressed the same level of Met and Gab1 proteins compared 
with parental HCC827 cells, they expressed much higher levels of 
phosphorylated Met and Gab1 (Supplementary fig S2). 
Importantly, E7050 prevented the emergence of viable clones even under 
conditions of continuous exposure to gefitinib and HGF (Fig. 4B). These results 
suggest the potential of E7050 to abrogate the effects resulting from continuous 
exposure to HGF.  
E7050 circumvents HGF-induced resistance when combined with gefitinib 
in vivo 
To investigate the therapeutic efficacy of E7050 in vivo, we used the gefitinib 
resistance model previously described (13). We mixed PC-9 cells with the 
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HGF-high producing fibroblast cell line, MRC-5, and inoculated SCID mice 
subcutaneously with this mixture. Oral treatment with gefitinib and/or E7050 was 
started after the establishment of solid tumors on day 4. Consistent with previous 
observations, we found that treatment with gefitinib alone prevented the 
enlargement of tumors produced by the mixture of PC-9 and MRC-5 cells, but 
did not cause tumor regression. As gefitinib induces shrinkage of PC-9 tumors 
(13, 14), our results suggest that MRC-5 cells induced gefitinib resistance in vivo. 
Under these experimental conditions, treatment with E7050 alone did not inhibit 
tumor growth, whereas the combination of E7050 and gefitinib induced marked 
tumor regression (Fig. 5A and B). 
To confirm that E7050 inhibits Met/PI3K/Akt signaling in vivo, we assessed 
expression of phosphorylated Met and Akt in the xenograft tumors. 
Immunoprecipitation revealed that phosphorylated Met was detected in control 
tumors and gefitinib-treated tumors but not in tumors treated with E7050 
monotherapy or E7050 plus gefitinib (Fig 5C), indicating efficacy of E7050 as a 
Met kinase inhibitor. Moreover, we observed higher levels of phosphorylated Akt 
in control cancer cells, with this phosphorylation slightly decreased by either 
E7050 or gefitinib alone and markedly inhibited by the combination of E7050 and 
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gefitinib (Fig. 5D). In addition, there were no discernible differences in HGF 
concentrations between control and treated groups, when HGF protein 
concentrations were determined by EIA using lysates of tumors obtained after 5 
days of treatment (Supplementary fig S3). These results suggest that E7050 
overcame the gefitinib resistance associated with inhibition of the Met/Akt 
pathway. 
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Discussion 
HGF is a multifunctional cytokine that can be produced not only by cancer 
cells but also by stromal cells, such as fibroblasts. The HGF receptor, Met, and 
EGFR interact with each other and mediate redundant signaling (26). Elevated 
serum concentrations of EGFR ligands and HGF were detected in patients with 
NSCLC, and HGF expression has been associated with poor prognosis in 
patients resected for NSCLC (27-28). While the role of HGF in EGFR mutant 
lung cancer remained unclear, we observed HGF-induced EGFR-TKI resistance 
in EGFR mutant lung cancers (9). Moreover, many studies have shown the 
important roles of HGF in sensitivity to molecular targeted drugs. Our 
observations regarding EGFR-TKI in lung cancer were confirmed by subsequent 
studies (10, 29) and the concentrations of HGF in peripheral blood were found to 
be inversely correlated with clinical responses to EGFR-TKIs, in both EGFR 
mutant and wild-type lung cancer (30, 31). HGF was also found to cause 
resistance to sunitinib, a multi-kinase inhibitor, in renal cell carcinoma by 
compensating for inhibited angiogenesis (32). Taken together, these findings 
indicate the importance of HGF as a therapeutic target for drug resistance in 
cancer.  
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We have shown here that a new Met-TKI, E7050, reversed three 
HGF-induced resistance mechanisms in EGFR mutant lung cancer. First, E7050 
reversed HGF-induced gefitinib resistance by inhibiting Met phosphorylation and 
thereby suppressing the downstream PI3K/Akt pathway. Second, E7050 
inhibited the HGF-induced resistance to next-generation EGFR-TKIs, 
irreversible EGFR-TKIs and mutant-selective EGFR-TKIs. Third, E7050 
prevented the emergence of resistant clones induced by continuous exposure to 
HGF.  
An interaction between HGF and Met amplification has been associated with 
EGFR-TKI resistance in lung cancer (10). In the presence of gefitinib, continuous 
exposure to HGF accelerated the expansion of preexisting Met amplified 
HCC827 cells. Unexpectedly, when we cultured HCC827 cells with gefitinib and 
HGF for 30 days, we found that the percentage of cells with Met amplification 
was not increased. The reason we failed to detect expansion of clones with Met 
amplification, however, remains unclear. Transfection of the HGF gene into 
HCC827 cells produced HCC827/HGF cells, which constitutively produce HGF. 
These cells, however, were selected in the presence of geneticin but not gefitinib, 
with several clones showing amplification of Met (data not shown). Therefore, 
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this phenomenon may be unique to a population of EGFR mutant lung cancer 
cells observed only under selection pressure with gefitinib plus an as yet 
unknown concentration of HGF. 
Met was shown to be constitutively phosphorylated in human lung cancer cell 
lines, with the degree of phosphorylation not always correlated with susceptibility 
to EGFR-TKIs (33). Indeed, previous studies reported that the level of Met 
phosphorylation was higher in HCC827 cells than in other EGFR mutant cell 
lines (9, 10, 13, 29). Similar to these results, we also observed that the level of 
Met phosphorylation was higher in HCC827 cells than in PC-9 and Ma-1 cells 
(Supplementary fig S4). While the bands for pMet in our study seem to be 
weaker than those in a previous study (34), ours and previous studies constantly 
showed that Met phosphorylation in HCC827 cells was higher than that in other 
EGFR mutant cells. While the difference in the intensity of pMet bands between 
our study and the previous is unclear, it might be due to minor differences in 
experimental conditions, including the exposure time at western blot and the cell 
culture conditions. Regarding HGF-triggered EGFR-TKI resistance, previous 
studies also support our findings that while HCC827 cells were highly sensitive 
to EGFR-TKIs, further Met activation or phosphorylation resulted in inducing 
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resistance to EGFR-TKIs (10, 29, 35). We confirmed that knockdown of Met by 
siRNA canceled HGF-induced resistance in HCC827 cells (9). Moreover, it was 
reported that Met amplification resulted in increased level of Met phosphorylation 
and caused resistance to EGFR-TKIs in HCC827 cells (8). This accumulating 
evidence indicates that constitutive Met phosphorylation is insufficient and 
further activation by HGF or Met amplification may be necessary to induce 
EGFR-TKI resistance in HCC827 cells. Therefore, there may be a threshold 
level for Met phosphorylation to sufficiently cause EGFR-TKI resistance. 
E7050 inhibits both Met and VEGFR2 kinases (16). In vitro, PC-9 and 
HCC827 cells express little VEGFR2 (data not shown). E7050 did not 
significantly inhibit the growth of these cell lines, and the anti-VEGF antibody 
bevacizumab did not augment the susceptibility of these cell lines to gefitinib 
(data not shown). These results suggest that the in vitro anti-tumor effects of 
E7050, when combined with gefitinib and HGF, may be largely due to Met 
inhibition. In vivo, we found that very high concentrations of HGF, obtained by 
HGF gene transfection into cancer cells, increased intratumor vessel density 
(submitted for publication elsewhere). However, HGF concentrations were lower 
in our xenograft model of mixed PC-9 and MRC-5 cells (fibroblasts) than in 
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xenograft tumors produced by HGF-gene transfected lung cancer cells. We 
observed no difference in intratumor vessel density between tumors induced by 
PC-9 cells alone and tumors induced by PC-9 and MRC-5 cells (Supplementary 
fig S5). In addition, E7050 did not affect significantly the vessel density in tumors 
induced by PC-9 and MRC-5 cells. Collectively, these observations suggest that 
the anti-tumor effects of E7050 in this resistance model may not be 
predominantly due to angiogenesis inhibition. 
 The secondary T790M mutation in EGFR is the most prominent mechanism of 
acquired resistance to EGFR-TKIs in EGFR mutant lung cancer, with this 
mutation detected in about 50% of these patients (4). The T790M mutation 
increases the affinity of EGFR for ATP, decreasing the binding of EGFR to 
EGFR-TKIs, and inducing resistance to the latter agents (36). EGFR mutant lung 
cancer cells with the T790M secondary mutation, however, remain susceptible to 
EGFR mediating signaling and are thought to be manageable by inhibition of 
EGFR-mediated signaling (37). Preclinical studies have shown that 
next-generation EGFR-TKIs, irreversible TKIs and mutant EGFR-selective TKIs 
have activity against gefitinib-resistant tumors with EGFR T790M secondary 
mutation (21 – 23). However, several irreversible EGFR-TKIs, including 
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BIBW2992 (38) and HKI-272 (39), failed to meet primary endpoints in clinical 
trials of patients with EGFR-TKI refractory lung cancer. High concentrations of 
HGF have been frequently detected in tumors with EGFR-T790M secondary 
mutations showing acquired resistance (10, 40, 41). In addition, we found 
previously (11) and confirmed here that HGF induces resistance to irreversible 
EGFR-TKIs in EGFR mutant lung cancer cells. Taken together, these 
observations suggest that HGF expressed in tumors with acquired resistance 
and EGFR T790M secondary mutations induce resistance to irreversible 
EGFR-TKI. As E7050 reversed the resistance to irreversible and 
mutant-selective EGFR-TKIs, it may augment the therapeutic efficacy of 
next-generation EGFR-TKIs in EGFR mutant lung cancer patients with acquired 
resistance to the EGFR T790M secondary mutation. These ideas further 
illustrate the necessity of methods to select patients who develop EGFR-TKI 
resistance due to HGF.  
In conclusion, we have presented preclinical evidence showing that a new 
Met kinase inhibitor, E7050, may overcome HGF-induced resistance in EGFR 
mutant lung cancer. Further evaluation of E7050 in clinical trials is warranted to 
improve the outcomes of patients with EGFR mutant lung cancer. 
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Legends for figures 
Figure 1. E7050 reverses resistance to EGFR-TKIs induced by exogenous HGF. 
A, PC-9 and HCC827 cells were incubated with various concentrations of 
gefitinib, with or without HGF (20 ng/ml). B, PC-9 and HCC827 cells were 
incubated with various concentrations of E7050, with or without HGF (20 ng/ml) 
and/or gefitinib (0.3 μM). C, Cells were cocultured in Transwell chambers 
separated by 8 μm pore filters. PC-9 and HCC827 cells (8 ×103 cells/700 μL) 
with gefitinib and or E7050 (0.3 μM) were placed in the lower chambers, and 
MRC-5 fibroblasts (104 cells/300 μL), producing high concentrations of HGF, 
were placed in the upper chambers. After 72 h, the upper chambers were 
removed, and cell growth was measured using the MTT-assay. Bars indicate SD. 
*p<0.01. 
 
Figure 2. E7050 reverses resistance to EGFR-TKIs induced by endogenous 
HGF. 
 A, Cells (2×105/2 ml) were incubated for 48 h, and concentrations of HGF in the 
culture supernatants were determined by ELISA. B, HCC827/Vec and 
HCC827/HGF cells were incubated with various concentrations of gefitinib, with 
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or without E7050. Cell growth was determined by MTT assays. C, HCC827/Vec 
and HCC827/HGF cells were incubated with HGF (20 ng/ml), E7050 (1 μM), 
and/or gefitinib (1 μM) for 1 h. The cell lysates were harvested and 
phosphorylation of indicated proteins was determined by western blotting. D, 
HCC827/HGF cells were treated with or without ErbB3, Met, or Gab1 siRNA or 
scrambled siRNA for 24 h, followed by further incubation in medium for 48 h. The 
cell lysates were harvested and western blotting was performed to determine the 
expression of the indicated proteins. Cell growth after 72h was determined using 
MTT assays. Bars indicate SD. *p<0.01. 
 
Figure 3. E7050 reverses HGF-induced resistance to next-generation 
EGFR-TKIs in H1975 cells. H1975 cells were incubated for 72 h with various 
concentrations of BIBW2992 (A), an irreversible EGFR-TKI, and WZ4002 (B), a 
mutant-selective EGFR-TKI, in the presence or absence of HGF (20 ng/ml) 
and/or E7050 (1 μM). Cell growth was determined by MTT assays. Bars indicate 
SD. 
 
Figure 4. E7050 prevents the emergence of gefitinib-resistant HCC827 cells 
 American Association for Cancer Research Copyright © 2012 
 on February 14, 2012clincancerres.aacrjournals.orgDownloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on February 8, 2012; DOI:10.1158/1078-0432.CCR-11-1171
 40
with amplified Met induced by continuous exposure to HGF. A, HCC827 
cells were incubated with or without gefitinib (1 μM), HGF (20 ng/ml), and/or 
E7050 (1 μM), changing the medium every 3 days. After 30 days, viable colonies 
were stained with crystal violet. B, Representative cultures. 
 
Figure 5. E7050 circumvents HGF-induced resistance when combined with 
gefitinib in vivo. A, PC-9 cells (5×106) with or without MRC-5 cells (5×106) were 
inoculated subcutaneously into SCID mice (N=6) on day 0. The mice began 
treatment with oral gefitinib (25 mg/kg/day) and/or E7050 (50 mg/kg/day), on day 
4. The tumor area was measured every 3 or 4 days and the tumor volume was 
calculated as described in Materials and Methods. Bars show SE of the means
±SD. p<0.01. B, Macroscopic appearance of treated tumors harvested on day 
17. C, Expression of phosphorylated Met in harvested tumors. Met protein was 
immunoprecipitated by anti-Met antibody. Then, phosphorylated Met and Met 
protein were detected by anti-phosphotyrosine antibody and anti-Met antibody, 
respectively. D, Expression of phosphorylated Akt in the harvested tumors. 
Frozen sections were immunohistochemically stained with anti-phospho Akt 
antibody. Original magnification, ×200. 
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